Latest Emerging Markets News

Healthcare stocks split into two stories this week: big names sold off hard, while a few small caps ran on clear news. The biggest moves came from a sharp fall in Pro Medicus and Cochlear, while Noxopharm jumped after a top-tier journal publication.

Minbos Resources has appointed Rob Newbold as Acting CEO following the resignation of Lindsay Reed, while grappling with administrative and shareholder challenges delaying its key phosphate project in Angola.

GQG Partners delivered solid full-year 2025 results, with funds under management climbing 7.1% to US$163.9 billion and net income increasing 7.3% to US$463.3 million, despite net outflows. The firm maintained a strong dividend payout, reflecting confidence in its sustainable growth strategy.

GQG Partners reported a 7.1% increase in funds under management for 2025, driven by strong investment performance despite net outflows, while declaring a solid fourth-quarter dividend.

Cochlear Limited reported a modest 1% rise in HY26 sales revenue to $1.176 billion, but underlying net profit fell 9% amid slower-than-expected contract renewals for its new Nucleus Nexa implant system. The company anticipates a stronger second half and maintains full-year guidance at the lower end of its forecast.

Cochlear Limited reported a modest 1% rise in sales but a 9% fall in underlying net profit for the half year ended December 2025, as the rollout of its innovative Nucleus Nexa System faced longer-than-expected regulatory and contract hurdles. The company anticipates a robust second half driven by broader product availability and service growth.

Cochlear Limited posted a modest 1% increase in sales revenue for the half year ending December 2025, while underlying net profit fell 9%, impacted by cloud computing costs and a slower-than-expected Nexa System rollout. The company maintains its dividend and outlines cautious FY26 guidance.

Breville Group Limited has reported a record half-year revenue of AUD 1.1 billion, overcoming US tariff challenges through strategic manufacturing shifts and robust product innovation. The company’s steady profitability and geographic expansion signal a confident growth trajectory.

GQG Partners reported a rise in Funds Under Management to USD 165.7 billion as of January 2026, buoyed by strong investment performance despite notable net outflows during the month.

TruScreen has been confirmed as a superior primary cervical cancer screening device in the world’s largest opto-electronic study, outperforming traditional cytology and matching HPV testing accuracy.

Fortuna Metals has reported significant high-grade rutile mineralisation at its Mkanda project in Malawi, with assays from 96 drill holes revealing a mineralised footprint extending over 25km. The Malawi government has confirmed the company’s exemption from raw mineral export restrictions, supporting its in-country beneficiation plans.

WAM Active Limited has launched a $51.4 million pro-rata entitlement offer at a 7.8% discount to the recent share price, alongside a $19.3 million institutional placement to meet strong investor demand. The capital raising aims to bolster the company’s proven Australian equity investment strategy while offering shareholders fully franked dividends on new shares.